AASLD 2020
13-16 November, 2020
Digital edition
ENYO Pharma attended the 2020 digital edition of AASLD meeting.
The meeting confirms vonafexor (EYP001, FXRag) unique positioning for HBV and possible differentiated profile for NASH with ph2s on track to deliver in H1 2021.
We also presented a poster describing a novel small molecule modulating the mitochondrial NEET proteins that improves inflammation and fibrosis in liver and kidneys of NASH mice :
Download the poster (PDF)